CDMO Blog

Scaling-Up Production of Pluripotent Stem Cells Part 2 – Key Considerations for Successful Scale-Up

close

Categories

See More

Subscribe to Email Updates

Popular Stories

Viral Aggregation in Downstream Processing of Lentiviral Vectors May 11, 2020
IQ, OQ and PQ: Why Are They Important in the Manufacturing of Cell and Gene Therapies? Oct 24, 2019
CDMOs: The Good, the Great and the Exceptional (and How to Tell the Difference) Aug 12, 2020
Five Steps to Ensure Your Cell and Gene Therapy Product Is GMP Compliant Oct 30, 2019
5 Considerations for Scaling-Up PSC-Derived Cell Therapies Mar 04, 2021
Categories | Subscribe | Popular
09 Jun 2021

Scaling-Up Production of Pluripotent Stem Cells Part 2 – Key Considerations for Successful Scale-Up

In Part 1 of this series we covered some basic definitions and reviewe...

04 Mar 2021

5 Considerations for Scaling-Up PSC-Derived Cell Therapies

A core regenerative medicine approach is cell replacement for the repa...

24 Oct 2019

How Can a Closed CAR-T Manufacturing Process De-Risk Your Process, Reduce Costs and Improve Efficiency?

In a previous post we introduced chimeric antigen receptor T-cell (CAR...

24 Oct 2019

What is a Bioreactor and How is it Used in Cell and Gene Therapy?

Simply put, a bioreactor is a stand-alone cell culture vessel enabled ...

22 Oct 2019

How Can a Contract Development and Manufacturing Organization (CDMO) Advance a Cell & Gene Therapy Product?

  Making the Decision to Engage a CDMO

Tell us what you thought about this post.
Business people meeting around table in modern space

Subscribe to our blog.

Receive updates on the latest trends in cell & gene therapy.

Subscribe to Email Updates

© 2021 All Rights Reserved